Comprehensive genomics using the Illumina Beadstation 500

描述（由申请人提供）：购买Illumina Beadstation 500将使我们的微阵列设施从使用内部cDNA平台进行基因表达研究转移到商业平台，以与我们现在收取的价格相当的价格提供更好的服务。这是在有必要为我们的内部阵列重新制作PCR产品以继续生产的时候，这是一个昂贵且耗时的过程。购买Illumina Beadstation 500还将使我们能够为基因表达研究提供一个比我们一直使用的平台更好，更完整的平台，并且可以提供其他研究人员使用该平台轻松比较和确认的数据。由于转录本覆盖率与Affyssin基因表达平台相同，因此也可以在这些平台之间进行比较。除了基因表达研究，我们现在还能够提供以前无法提供的新的基因组服务。新服务将包括SNP基因分型、使用固定样本的基因表达、基因拷贝数变化和DNA甲基化研究，从而提供更完整的遗传评估平台。我们已经提出了项目，并在某些情况下，从试点研究的初步结果，描述实验需要访问这些技术的每一个在其他学术机构的Wistar教师和用户进入新的研究与重要的健康相关的目标。这些项目包括开发用于肺癌早期检测的生物标志物的项目，肺癌仍然是癌症相关死亡的主要原因，一个鉴定黑色素瘤干细胞特征的项目，这可能导致这种恶性肿瘤治疗的新靶点，一个绘制小鼠模型系统中再生的复杂特征的项目，这可能导致对器官修复过程的新思考方式，以及新的研究来确定肺癌和皮肤T细胞淋巴瘤治疗反应的标志物。获得这些技术对于新的赠款申请和扩大我们的服务以包括评估在基因表达水平上无法检测到的遗传变化将是重要的。

DESCRIPTION (provided by applicant): The purchase of the Illumina Beadstation 500 will allow our microarray facility to move from using an in house cDNA platform for gene expression studies to a commercial platform that provides a better service at a price comparable to what we now charge. This comes at a time when it would be necessary to remake the PCR products for our in house arrays to continue their production, a costly and time consuming process. The purchase of the Illumina Beadstation 500 will also allow us to provide a better and more complete platform for gene expression studies than the one we have been using and one which will provide data that can easily be compared and confirmed by other investigators using this platform. Since the transcript coverage is the same as the Affymetrix gene expression platform, comparisons across these platforms will also be possible. In addition to gene expression studies, we will now be able to offer new genomic services that we could not previously provide. The new services will include SNP genotyping, gene expression using fixed samples, gene copy number changes and DNA methylation studies, thus providing access to a more complete panel of genetic assessment platforms. We have presented projects, and in some cases preliminary results from pilot studies, that describe experiments requiring access to each of these technologies as the Wistar faculty and users at other academic institutions move into new studies with important health related objectives. These projects include programs to develop biomarkers for early detection of lung cancer, which remains a primary cause of cancer related deaths, a project to identify characteristics of melanoma stem cells, which may lead to new targets for therapy for this recalcitrant cancer, a project to map the complex traits for regeneration in a mouse model system that may lead to new ways of thinking about repair processes in organs, and new studies to identify markers for response to therapy in both lung cancer and Cutaneous T-cell lymphoma. Access to these technologies will be important for new grant applications and to expand our services to include the assessment of genetic changes that are not detectable at the levels of gene expression.